Evidence map›Paper›PMID 36803831›Full record

ReviewCancer cell international2023

MicroRNA-122 in human cancers: from mechanistic to clinical perspectives.

Mahboobeh Faramin Lashkarian, Nasrin Hashemipour, Negin Niaraki, Shahrad Soghala, Ali Moradi, Sareh Sarhangi, Mahsa Hatami, Fatemehsadat Aghaei-Zarch, Mina Khosravifar, Alireza Mohammadzadeh and 4 more

Open access · goldAbstract readReview
In one paragraph

Review in Cancer cell international, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 1 pooled it
28.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 1 synthesis or guideline pooled it, 115 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Loss of miR-122 promotes cell migration and poor prognosis in triple-negative breast cancer treated by neoadjuvant chemotherapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Long non-coding RNAJournal of biomedical research · 2025
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 11 institutions in 2 countries.

Mahboobeh Faramin Lashkarian *Department of Molecular Genetics, Central Tehran Branch, Islamic Azad University, Tehran, Iran.
Nasrin Hashemipour *Department of Biology, School of Science, Yazd University, Yazd, Iran.
Negin NiarakiDepartment of Cell and Molecular Biology, School of Life Sciences and Biotechnology, Shahid Beheshti University, Tehran, Iran.
Shahrad SoghalaDepartment of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran.
Ali MoradiSchool of Advanced Sciences and Technology, Tehran Medical Sciences Branch, Islamic Azad University, Tehran, Iran.
Sareh SarhangiDepartment of Genetics, School of Advanced Sciences and Technology, Tehran Medical Sciences Branch, Islamic Azad University, Tehran, Iran.
Mahsa HatamiDepartment of Medical Genetics, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Fatemehsadat Aghaei-ZarchSchool of Medicine, Kerman University of Medical Sciences, Kerman, Iran.
Mina KhosravifarInstitute of Diabetes, Obesity, and Metabolism, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Alireza MohammadzadehDepartment of Microbiology, School of Medicine, Infectious Diseases Research Center, Gonabad University of Medical Sciences, Gonabad, Iran.
Sajad NajafiDepartment of Medical Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. sajadnajafi1990@yahoo.com.
Jamal MajidpoorDepartment of Anatomy, Faculty of Medicine, Infectious Disease Research Center, Gonabad University of Medical Sciences, Gonabad, Iran. jmajidpoor@gmail.com.
Poopak FarniaMycobacteriology Research Centre, National Research Institute of Tuberculosis and Lung Disease, Shahid Beheshti University of Medical Sciences, Tehran, Iran. p.farnia@sbmu.ac.ir.
Seyed Mohsen Aghaei-ZarchDepartment of Medical Genetics, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. mosenaghaei123@gmail.com.
Gonabad University of Medical Sciences · IRIslamic Azad University Medical Branch of Tehran · IRShahid Beheshti University of Medical Sciences · IRAja University of Medical Sciences · IRIslamic Azad University Central Tehran Branch · IRIslamic Azad University, Science and Research Branch · IRKerman University of Medical Sciences · IRMasih Daneshvari Hospital · IRShahid Beheshti University · IRUniversity of Pennsylvania · USYazd University · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MicroRNAs (miRNAs) are endogenous short non-coding RNAs that can regulate the expression of target genes post-transcriptionally and interact with mRNA-coding genes. MiRNAs play vital roles in many biological functions, and abnormal miRNA expression has been linked to various illnesses, including cancer. Among the miRNAs, miR-122, miR-206, miR-21, miR-210, miR-223, and miR-424 have been extensively studied in various cancers. Although research in miRNAs has grown considerably over the last decade, much is yet to be discovered, especially regarding their role in cancer therapies. Several kinds of cancer have been linked to dysregulation and abnormal expression of miR-122, indicating that miR-122 may serve as a diagnostic and/or prognostic biomarker for human cancer. Consequently, in this review literature, miR-122 has been analyzed in numerous cancer types to sort out the function of cancer cells miR-122 and enhance patient response to standard therapy.

Indexed as

CancermiR-122PathogenesisPrognosisTherapy

Identifiers

PMID36803831
PMCPMC9940444
OpenAlexW4321371253

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.